GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Laboratorios Farmaceuticos Rovi SA (XMAD:ROVI) » Definitions » Momentum Rank

Laboratorios Farmaceuticos Rovi (XMAD:ROVI) Momentum Rank : 3 (As of May. 20, 2024)


View and export this data going back to 2007. Start your Free Trial

What is Laboratorios Farmaceuticos Rovi Momentum Rank?

Laboratorios Farmaceuticos Rovi has the Momentum Rank of 3.

For Momentum Rank, we considered the residual momentum concept that was widely studied by Blitz and his colleagues as well as by Nobel Prize laureates Fama and French. However, we did not find any significant differences in the performances of stocks with different ranks of residual momentum. Therefore, we use traditional momentum instead.

Momentum Rank is determined using the standardized momentum ratio and other momentum indicators. The standardized momentum ratio is the average of the performances from 12 months ago to 1 month ago and 6 months ago to 1 month ago, divided by the beta of the stock over the past 12 months. To calculate the momentum ratio today, we would use the average of the two performance numbers.

For momentum, we found that stock price performance does not have a monotonic correlation with the momentum ratio. The stocks with the highest momentum ratios perform worse than those at about the 70th percentile. Therefore, for the momentum rank, we ranked the stocks at about the 70th percentile of the momentum ratio as the highest at 10.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.


Competitive Comparison of Laboratorios Farmaceuticos Rovi's Momentum Rank

For the Biotechnology subindustry, Laboratorios Farmaceuticos Rovi's Momentum Rank, along with its competitors' market caps and Momentum Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Laboratorios Farmaceuticos Rovi's Momentum Rank Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Laboratorios Farmaceuticos Rovi's Momentum Rank distribution charts can be found below:

* The bar in red indicates where Laboratorios Farmaceuticos Rovi's Momentum Rank falls into.



Laboratorios Farmaceuticos Rovi Momentum Rank Related Terms

Thank you for viewing the detailed overview of Laboratorios Farmaceuticos Rovi's Momentum Rank provided by GuruFocus.com. Please click on the following links to see related term pages.


Laboratorios Farmaceuticos Rovi (XMAD:ROVI) Business Description

Traded in Other Exchanges
Address
Julian Camarillo, 35, Madrid, ESP, 28037
Laboratorios Farmaceuticos Rovi SA is a biotechnology company engaged in the research, development, manufacturing, and marketing of small molecule and specialty biologic drugs. The company has a diversified portfolio of products that it markets in Spain through its specialized sales force of specialist physicians, hospitals and pharmacies. Laboratorios' research and development pipeline is focused on the expansion of applications, indications, and alternative mechanisms of action for heparin-derived products. The company aims to obtain new pharmaceutical products that enable the regular administration of formulations that are administered daily in chronic and prolonged treatments. Its two segments are Manufacturing and Marketing.

Laboratorios Farmaceuticos Rovi (XMAD:ROVI) Headlines

From GuruFocus

Pluto TV Partners With TiVo to Expand the TiVo+ Content Network

By Business Wire Business Wire 05-05-2020

Rovi Corp. (ROVI) EVP & CFO James Budge sells 29,583 Shares

By GuruFocus Research GuruFocus Editor 01-07-2011

Rovi Corp. (ROVI) President and CEO Alfred J Amoroso sells 96,461 Shares

By GuruFocus Research GuruFocus Editor 03-04-2011

Rovi Corp. (ROVI) EVP & CFO James Budge sells 10,833 Shares

By GuruFocus Research GuruFocus Editor 02-03-2011